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Catholic Institute of Lille, Lille, FranceObjective. Programmed cell death plays a critical role in various physiological processes. To investigate its possible
pathogenic role in primary varicose veins we studied histological changes in surgical specimens from human varicose veins.
In varicose and healthy veins, we also determined the number of cells in apoptosis, and investigated mediators regulating the
intrinsic apoptotic mitochondrial pathway (Bax and caspase 9).
Methods. A total 23 varicose veins were obtained from 18 patients undergoing lower-extremity varicose vein surgery for
primary varicose disorders. We used nine healthy veins obtained from nine patients undergoing distal arterial bypass
grafting surgery as controls. The venous segment analysed was the distal part of the greater saphenous vein. Specimens for
histological examination were stained with hematoxylin and eosin, trichromic and Victoria blue. Cell apoptoses and
mediators of the mitochondrial pathway were detected in the media by immunohistochemistry using antibodies to peroxidase
in situ apoptosis, Bax and caspase 9. Results were expressed as indexes for the three antibodies tested. The Mann–Whitney
test was used to compare the results obtained in the two groups.
Results. Varicose vein specimens exhibited a more disorganised architecture than healthy veins and showed an increased
number of collagen fibres and a decrease in the density and size of elastic fibres. All anti-apoptotic antibodies tested detected
significantly fewer immunoreactive cells in tissue sections from the media of varicose veins than of healthy veins (peroxidase
in situ, varicose veins (VV) median 2.4% (inter-quartile range 1.6–3.9) versus control (C) 14% (IQR 8.8–19); Bax, VV
1.4% (IQR 0.36–2.4) versus C 11% (IQR 7.6–15); and caspase 9, VV 1.7% (IQR 0.06–3.4) versus C 10% (IQR 9.1–12),
PZ0.0001 (Mann–Whitney test).
Conclusion. Apoptosis is down regulated in the medial layer of varicose veins. This dysregulation of the cellular mechanism
that maintains normal tissue integrity is mediated through the intrinsic apoptotic pathway and may be among the causes of
primary varicose veins.Keywords: Apoptosis; Varicose vein; Primary varicose veins; Vascular apoptosis; Mitochondrial pathway.Introduction
Even today, we know surprisingly little about how and
why primary varicose veins develop. Despite the
numerous aetiological factors including pregnancy,1
obesity,2 heredity or ethnicity,3,4 no satisfactory under-
lying mechanism has been proposed to explain the
onset and progression of primary superficial venous
insufficiency. When Estienne and Canano first dis-
covered the venous valves, valvular failure at the
sapheno-femoral junction was regarded as the pri-
mary event with secondary failure of more distaling author. Dr E. Ducasse, Unit of Vascular Surgery,
ode-Pellegrin, Tripode 5e`me, 33076 Bordeaux, France.
: eric.ducasse@online.fr
0316+ 08 $35.00/0 q 2004 Elsevier Ltd. All rights reservalves and complete superficial venous insufficiency.5,6
Others later refuted this hypothesis.7
Recent evidence implies that superficial venous
insufficiency arises from a structural weakness in the
vein wall. These weaknesses could reflect the collagen
or elastin content,8–10 or the concentration of metallo-
proteinases or inhibitors in the extracellular matrix of
the venous wall.11 A recent ultrasonic analysis of the
sapheno-femoral junction and the distribution of
varicosities support a primary wall abnormality
predisposing to venous dilatation.12
Some evidence suggests that wall weakness in the
varicose veins and the progressive replacement of
normal components of the venous wall leading to
dilatation and superficial venous insufficiency which
is associated with a decrease in the number of cells
undergoing apoptosis.13–15 Apoptosis, programmedEur J Vasc Endovasc Surg 29, 316–323 (2005)
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Apoptosis in Varicose Veins 317cell death, has attracted great attention in recent years.
Apoptosis is a normal process in development,
morphogenesis and tissue regulation. Improperly
regulated apoptosis, with defective DNA repair
mechanisms and cell cycle alteration can nevertheless
contribute to several pathological conditions including
cancer, Alzheimer’s disease, spinal muscular atrophy,
ischemic cardiac damage and auto-immune syn-
drome.16–18 Apoptosis is a multifactorial phenomenon
caused by specific activation of a family of intracellular
cysteine proteases known as caspases (cysteine aspar-
tyl-specific proteases) inducible by various stimuli.19
Schematically, two diverse pathways are distin-
guished. The intrinsic pathway (mitochondrial path-
way or type I) regulated by apoptosis promoter
proteins such as Bax or Bcl-2 and specific caspases
(with motif caspase-associated recruitment domains—
CARD) involves the participation of mitochondria,
which release caspase-activating proteins into the
cytosol, thereby triggering apoptosis. The extrinsic
pathway (trans-membrane pathway or type II), regu-
lated by proteins such as fas, and the tumour-necrosis
factor receptor (TNF-R) family of proteins, involves
specific caspases (with motif death effector domains—
DED) connecting ligand binding at the cell surface to
apoptosis induction.20–23
In this study of human surgical specimens, we
evaluated histological changes in varicose veins. We
also determined the number of cells in apoptosis
detected by 3 0OH DNA termini on DNA fragments by
a specific immunohistochemical assay in varicose and
healthy veins. We also determined mediators regulat-
ing the intrinsic apoptotic mitochondrial pathway in
varicose veins and healthy veins by detecting
expression of Bax, considered a potent intrinsic
apoptosis promoter,24–26 and caspase 9, a 46–48 kDa
protein precursor of the mitochondrial apoptotic
pathway.27–29 We did not detect expression of Bcl-2
because its role as a promotor or inhibitor of apoptosis
remains ambiguous insofar as previous studies found
no differences in Bcl-2 levels in varicose and healthy
veins.13Material and MethodsCohort
A total of 23 varicose veins were obtained from 18
patients who were undergoing lower-extremity var-
icose vein excision. In five patients bilateral varicose
veins were removed and included in the study. The
characteristics of patients are given in Table 1. Theoperative indications were distributed according to
the clinical etiological anatomical and physiopatholo-
gical (CEAP) classification as class 2 (nZ2), class 3 (nZ
10) and class 4 (nZ6). All patients had a primary
varicose disorder with no specific venous risk factors
and 16 of the 18 patients had a direct familial linkage.
All patients were symptomatic for 1 year or longer. A
total nine healthy veins (controls) were obtained from
nine patients who were undergoing distal arterial
bypass grafting surgery. For all the venous specimens,
the segment analysed was the greater saphenous vein
(GSV) 1 cm distal to its connection with the common
femoral vein. The segment analysed in the varicose
vein group was removed before vein stripping.
In all patients with varicose veins preoperative
venous duplex ultrasound scanning showed greater
saphenous vein reflux filling from the deep venous
system and dilatation of GSV measuring 5 mm or
more in diameter at the point of sampling. None of the
patients had deep vein reflux or evidence of current or
previous venous thrombosis. The control group con-
sisted of patients in whom preoperative investigation
and duplex ultrasound investigation prior to distal
arterial bypass grafting surgery demonstrated no
evidence of venous reflux or dilatation. None had
diabetes or a history of venous disease. In one control
patient the vein used for the bypass was partially
dilated with no apparent global dilatation and was
considered adequate for a distal bypass. In this patient,
a distal segment of the GSV was removed for
examination. In the control group, neither calcification
nor parietal thrombus were histologically evident on
the venous segment.30,31
The study was approved by the hospital ethics
committee and all the venous segments were removed
with patients’ informed written consent.Tissues specimens
All venous segments were fixed in 10% neutral
buffered formalin solution and paraffin embedded.
Vein specimens were sectioned (3 mm) (LEICA JUNG-
RM-2035) perpendicular to the axis of the vessel; when
the original venous segment was long enough the
whole block was sectioned and sections were fixed
each 5 mm (two to five sections per block/slide).Histology
Specimens were stained with haematoxylin and eosin
for routine histological evaluation. Changes in the
localization, form and density of collagenous connec-
tive fibres in the parietal wall of varicose veins andEur J Vasc Endovasc Surg Vol 29, March 2005
Table 1. Characteristics of the 27 patients with healthy and varicose
veins
Varicose veins
(nZ23)
Healthy veins
(nZ9)
P value
Number of
patients
18* 9
Gender
Men:women 4:14 4:5
Mean age (years) 54 (G16) 62 (G12) !0.05
Height (cm) 165 (G6.1) 168 (G4.8)
Weight (kg) 73 (G20) 70 (G11)
Body mass index
(BMI)
26.4 (G5.7) 24.8 (G2.9) !0.05
!20 3 1
20–26 6 5
O26 9 3
Clinical etiological anatomical and physiopathological classification
Type 2 2 –
Type 3 10 –
Type 4 6 –
All data are expressed as means plus or minus SD.
* In five patients bilateral varicose veins were removed and
included in the study.
E. Ducasse et al.318healthy veins were detected by trichrome staining.
Changes in the localization, form and density of elastic
fibres in specimens from varicose and healthy veins
were examined in Victoria blue-stained specimens.Immunohistochemical detection
Cell apoptoses and mediators of the intrinsic mito-
chondrial pathway were detected with three primary
antibodies: Apoptagw peroxidase in situ Apoptosis
Detection Kit-S7101 (BIOTECH, Andover, MA, USA)
(diluted: 33:110); rabbit polyclonal bax P-19-SC526
(SANTA CRUZ Biotechnology, INC) (diluted 1:40);
and rabbit polyclonal antibody caspase 9 Ab-4 (Cat
RB-1205-P1ABX) (NEOMARKERS, Fremont, CA,
USA) (diluted 1:40).32 Serial formalin-fixed paraffin-
embedded tissue sections were dewaxed and rehy-
drated by sequential immersions in three changes of
xylene for 5 min each wash followed by immersion in
absolute, 95 and 70% ethanol for 3 min each bath and
in phosphate-buffered saline (PBS) for 5 min. The
tissue was pretreated by applying proteinase K
(20 mg/ml) for 15 min at room temperature directly
onto the slide (60 ml/5 cm2). The specimen was
washed in two changes of dH2O for 2 min each
wash. Endogenous peroxidase was quenched in PBS
containing 3% hydrogen peroxide for 5 min at room
temperature. Equilibration buffer was applied directly
to the specimen (75 ml). For the peroxidase in situ
detection, working strength TdTenzyme was immedi-
ately applied onto the section. The specimen was then
incubated in a humidified chamber at 37 8C for 1 h.Eur J Vasc Endovasc Surg Vol 29, March 2005Working strength stop buffer was applied for 10 min at
room temperature. Anti-digoxigenin conjugate was
applied to each specimen (65 ml/5 cm2) and specimens
were incubated in a humidified chamber for 30 min at
room temperature. Specimens were washed in four
changes of PBS for 2 min per wash. For Bax and
caspase 9 detection, biotinylated link was applied and
incubated 10 min at room temperature. Specimens
were rinsed with wash solution and placed in a wash
solution bath for 10 min. Streptavidin-HRP was
applied and specimens were incubated for 10 min at
room temperature. Specimens were rinsed with wash
solution and placed in a wash solution bath for 10 min.
For all specimens, peroxidase substrate was applied
(75 ml/5 cm2) to stain the specimens for 3–6 min.
Specimens were washed in three changes of dH2O
for 1 min each wash. Slides were incubated in dH2O
for 5 min at room temperature. Specimens were
stained in 0.5% methyl green for 10 min at room
temperature and washed in three changes of dH20.
Slides were then immersed 10 times each in the first
and second washes, and in the third wash 30 s without
agitation. The specimens were washed in three
changes of 100% N-butanol, mounted on silanised
slides and viewed under the optical microscope. On
samples from carcinoma the anti-apoptosis antibody
normally detects a large number of immunoreactive
cells.Quantification
For the histological analysis two fields per section
were examined for staining at 400!magnification. The
immunohistochemical expression of apoptosis was
determined according to the intensity of nuclear
staining and the density and morphology of chroma-
tin. Results were evaluated by two independent
investigators who were blinded to the patients’ clinical
findings; only inter-observer errors !2% were
allowed. Peroxidase in situ, Bax and caspase 9-
immunoreactive cells considered as positive for
apoptosis in the media layer were counted manually
at 400!magnification and seven random fields per
section were counted. Two to five sections per speci-
men were evaluated. Immunohistochemical positive
cell staining was not investigated in the intima and
vasa-vasorum because previous studies found no
differences in intimal apoptosis in varicose and
healthy veins.14 Nor was positive cell staining inves-
tigated in the adventitia because preliminary exper-
iments showed that this layer was severely and
diffusely disorganized and contained few positive
cells.13,14 The apoptotic index was calculated as the
Apoptosis in Varicose Veins 319number of positive cells in each field divided by
number total of cells in the field multiplied by 100.Statistical analysis
All data are expressed as medians and interquartile
ranges. Immunohistochemical results are expressed as
the apoptotic index for the three antibodies tested.
Data obtained were analyzed by the Mann–Whitney
test comparing the results obtained in the two groups.
A P value less than 0.05 was considered to be
statistically significant. Statistical analyses were per-
formed with StatView (SAS Institute, Cart, NC)
software.ResultsHistology
Varicose vein specimens exhibited a more disorga-
nised architecture than healthy veins. Trichrome
staining demonstrated an increased number of col-
lagen fibres in the media with a specific decrease in
smoothmuscle cells in the sub-intimal layer associated
with inhomogeneous thickness and organisation in the
media layer (Fig. 1(a) and (b)). The adventitial layer
was thinner in varicose veins than in healthy veins and
contained more collagen fibres. In varicose veins,
Victoria blue staining demonstrated a decrease in the
density and size of elastic fibres and increased fibre
degradation in the adventitial layer. In the media,
elastic fibres were fragmented with constant parcelled
interruption of the elastic lamina.Immunohistochemical stainingPeroxidase in situ apoptosis detection
The apoptotic index of positive cell staining differed
significantly in the two groups: varicose veins con-
tained fewer peroxidase in situ-positive cells than
healthy veins (Fig. 2(a) and (b)) (Table 2). Microscopy
without quantification showed that the vasa-vasorum
in the medial layer of varicose veins contained fewer
positive stained cells than healthy veins.Bax detection
The apoptosis promoter index of positive cell staining
differed significantly in the two groups: varicose veins
contained fewer Bax positive cells than healthy veins
(Fig. 3(a) and (b)) (Table 2).Caspase 9 detection
Again, the apoptosis promoter index of positive cell
staining differed significantly in the two groups:
varicose veins contained fewer caspase 9 positive
cells than healthy veins (Fig. 4(a) and (b)) (Table 2). At
microscopic examination of varicose veins, caspase 9
stained cells were localized in the sub-adventitial area
of the medial layer; no stained cells were detected in
the sub-endothelial media. In healthy veins, caspase 9
stained cells were homogeneously distributed in the
medial layer.Discussion
Our study has confirmed previous histological and
immunohistochemical reports,13–15 but in addition, by
analysing data from a large number of vein specimens
in a standardised and reproducible manner, we now
provide evidence implicating the mitochondrial
(intrinsic) pathway in the pathogenesis of human
primary varicose veins. By evaluating histological
changes in the architectural organisation and deter-
mining the quantity, morphology and distribution of
collagen and elastic fibres in varicose veins, we found
that immunoreactivity to apoptotic detection in the
medial layer was less prominent in varicose veins than
in healthy veins. Immunohistochemical staining
detected fewer specific mediators regulating the
intrinsic apoptosis pathway (Bax and caspase 9) in
the medial layer of varicose veins than of healthy
veins. These cellular findings suggest that deregulated
programmed cell death through the intrinsic mito-
chondrial apoptosis pathway promoter is among the
possible causes of primary varicose veins in humans.
Hence, we may need to add programmed cell death to
the list of previously suggested causes of primary
varicose veins including valvular changes or parietal
recasting by tissue metalloproteinases.5,6,11
The architecture and distribution of collagen and
elastic fibres in the varicose veins appeared diffusely
disorganised. This cellular disorganisation corre-
sponded to an increased number of collagen fibres in
the media and adventitia layers and a specific increase
in elastin fibre degradation. These pathologic histo-
logical features correspond exactly to fibrotic degra-
dation of the parietal wall and a loss of mechanical
properties in varicose veins.14,33
Deregulated apoptosis is a fundamental mechanism
in a variety of diseases including cancer, autoimmune
disorders, immunodeficiency, inflammation, ischemic
heart disease, stroke and neurodegenerative diseases.
For example, inappropriate expression of apoptosis
promoters on lymphocytes and other immune cellsEur J Vasc Endovasc Surg Vol 29, March 2005
Fig. 1. (a, b) Trichrome staining showing an increased
number of collagen fibres in the media (stained in blue)
associated with a non homogeneous organisation and fewer
smooth muscle cells in varicose veins (a) than in healthy
veins (b) (original magnification, !400).
Fig. 2. (a, b) Peroxidase in situ apoptosis detection showing
fewer peroxidase in situ-positive cells in varicose veins (a)
than in healthy veins (b) (original magnification, !400).
E. Ducasse et al.320has been documented in patients with HIV infection
and has been implicated in the loss of lymphocytes
that characterises this immunodeficiency syndrome.34
The down regulation of apoptosis has also been
recognised in patients with severe forms of spinal
muscular atrophy, a motor-neuron degenerative dis-
ease, and in most non-Hodgkin’s lymphomas.35–37
Conversely, upregulation of apoptosis has been
documented in autoimmune lymphoproliferative syn-
dromes, and in many common types of cancer.38–40
Although less is known about cell turnover in the
vascular wall, recent evidence shows that apoptosis is
inversely correlated with restenosis related to arterial
intimal hyperplasia after angioplasty and venousTable 2. Immunohistochemical quantification of the specimens
from healthy and varicose veins
Number of
positive
stained cells
(in %)
Varicose veins Healthy veins *P value
Peroxidase in
situ apoptosis
detection
2.4 (1.6–3.9) 14 (8.8–19) 0.0001
Bax detection 1.4 (0.36–2.4) 11 (7.7–15) 0.0001
Caspase 9
detection
1.7 (0.06–3.4) 10 (9.1–12) 0.0001
All data are expressed as median (interquartile range).
* By Mann–Whitney test.
Fig. 3. (a, b) Bax detection showing fewer positive cells in
varicose veins (a) than in healthy veins (b) (original
magnification, !400).
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Fig. 4. (a, b) Caspase 9 detection showing fewer positive cells
staining in varicose veins (a) than in healthy veins (b)
(original magnification, !400).
Apoptosis in Varicose Veins 321graft.41,42 In human specimens, recent investigations of
apoptotic activity in advanced atherosclerotic lesions
in segments of renal, coronary and carotid arteries
have shown increased apoptosis and intrinsic path-
way promotors including Bax.43 Because apoptosis
plays a major role in tissue homeostasis and mainten-
ance, the decreased cell turnover we observed in this
study could be a major determinant of the parietal
weakness in primary varicose veins.
Our cellular study of primary varicose veins
showed that fewer cells stained for the peroxidase in
situ apoptosis detection in varicose veins than in
healthy veins in the media layer. This cellular finding
confirms the only previous investigations indicating
that the process of programmed cell death is inhibited
in varicose veins.13,14 Nevertheless, one of these
studies reported a statistically significant decrease in
the apoptotic index in the adventitia of varicose veins
compared with control veins and no difference in the
medial layer.13 The discrepancy presumably reflects
the high sensitivity of the anti-apoptosis antibodies we
used for our immunohistochemical assays. Yet cell
cultures from varicose veins show that the main
component of the venous wall, smooth-muscle cells,
principally localised in the media, transform from
normally contractile to secretory cell types thus
leading to fibrotic degeneration in the varicose veinwall.44 Cell cycle changes in varicose veins mediate
smooth-muscle cell dedifferentiation from a contractile
to a secretory phenotype.45 In accordance with our
study and previous findings, the fibrotic degradation
typical of the varicose venous wall is associated with
dysregulation of apoptosis in the media layer.
The distinctive finding in this study was the
significantly weaker concomitant Bax and caspase 9
immune expression in varicose veins than in healthy
veins. In previous studies, decreased Bax expression in
varicose veins was associated with Bcl-x (without
specifying whether the immunoreactivity detected
was anti-apoptotic Bcl-xl or pro-apoptotic Bcl-xs) or
with Bcl-2 (an anti-apoptotic protein).13,14 Because, we
found no significant difference for either Bcl-x or Bcl-2
proteins in patients and controls we cannot specify the
precise role of the intrinsic pathway in apoptotic
dysregulation. The intrinsic pathway can be induced
by mitochondrial release of cytochrome c, induced by
various stimuli, including elevated levels of the pore-
forming pro-apoptotic Bcl-2 family, including Bax.
Within the cytosol, cytochrome c binds and activates
Apaf-1, thus binding and activating pro-caspase 9.46–48
Active caspase 9 serves as the apical caspase of the
intrinsic (mitochondrial) pathway, and directly cleaves
and activates the apoptotic effector protease, caspase
3.49,50 By associating Bax and caspase 9 in our studywe
clearly showed that the decreased cell turnover is
mediated by the intrinsic pathway.
A limitation of our study is the possible sex-linked
effect related to the preponderance of women (14 out
of 18) within the varicose vein group. This matter calls
for further investigation in studies determining poss-
ible associations between demographic characteristics
and immunohistochemical findings.
In conclusion, our results provide evidence of
decreased programmed cell death in the medial layer
of human primary varicose veins. Assay of specific
proteins indicates that the physiological decrease in
normal apoptosis is mediated through the intrinsic
mitochondrial-dependent pathway. Our findings on
the intrinsic pathway call for further investigations to
identify the specific promoter proteins involved.
Another pressing question is whether decreased
apoptosis is the cause or effect of varicose vein
formation.Acknowledgements
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